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Abstract
Arginine is well known semi-essential amino acid used in protein biosynthesis 
through several metabolic pathways. It is majorly obtained from nutrients sources 
and synthesized by the urea cycle in the body using citrulline. Arginine found to be 
involved in several mechanisms including; hormone synthesis, cell division, activa-
tion of the immune system, ammonia disposal and wound healing and also in the 
production of nitric oxide (NO) and polyamines. During cancer persistence, the 
biosynthesis of arginine is not sufficient to compensate for their higher nutritional 
requirements but extracellular availability of arginine is also required. Therefore, the 
consequences of arginine deprivation may represent a novel targeting therapy to cure 
cancer. The impact of different arginine deprivation agents and their mechanism of 
action always found to be correlated with NO and polyamine levels. Arginine depri-
vation strategy to hamper the proliferation of cancerous cells and their migration 
is represented as a new approach to cure cancer by inhibiting the argininosuccinate 
synthetase1 (ASS1) expression and NO and polyamines production. ASS1 is the first 
key enzyme that converts citrulline to arginine and numerous tumors such as hepa-
tocellular carcinoma, melanoma, mesotheliomas and renal cancer do not express 
ASS1 and main focused enzyme for cancer treatment. Degradation of arginine by 
the enzyme arginine deiminase (ADI) specifically triggers the arginine elimination 
and inhibition of cancer migration. Though, ADI is a microbial enzyme but has a 
high affinity to arginine and converts arginine into citrulline and NH3. This produced 
citrulline can be recycled back to arginine in normal cells where ASS1 expression is 
very high in comparison to ASS1-negative tumor cells. A modified form of ADI with 
pegylate (ADI-PEG20) has been formulated which showed both in-vivo and in-vitro 
activity against hepatocellular carcinoma and melanoma by inducing apoptosis. In 
this chapter, we have majorly discussed arginine production with different pathways 
and how its degradation into other metabolic active compounds involved in cancer 
treatment. Moreover, how arginine deprivation is directly taking part in the inhibi-
tion of cancer cell proliferation and its migration.
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1. Introduction
Arginine is essential for microbes and semi-essential for eukaryotes which 
play numerous crucial roles in cellular metabolism. The impact of arginine always 
considered as a nonessential amino acid because a cell can synthesize arginine its 
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own as per the requirement. But, during its limitation in the cells, it is necessary 
to acquire arginine from outside environment and this condition denoted arginine 
as a conditionally essential amino acid. Majorly, arginine is produced by two 
ways; from food sources and biosynthesized through urea cycle in the kidney [1]. 
The biosynthesis of arginine represented the conversion of citrulline to arginine 
by the enzymes arginosuccinate synthetase1 (ASS1) and arginosuccinate lyase 
(ASL). The role of enzyme ASS1 is the conversion of citrulline and aspartic acid 
to arginosuccinate, which then directly converted to arginine and fumaric acid by 
the enzyme ASL [2]. In case of bacteria, ornithine also indicated as a substrate to 
synthesize arginine by the enzyme ornithine transcarbamylase (OCT) [3]. Arginine 
is a precursor molecule for the formation of amino acids such as proline, glutamate 
and arginine itself and several other components like succinate, nitrate, nitrite, 
nitric oxide (NO), ammonia and CO2. It acts as an intermediate in urea cycle and 
precursor molecules for polyamine, creatine and proteins biosynthesis [4]. Arginine 
becomes necessary for growth and promotes wound healing by stimulating the 
release of growth hormones such as insulin-like growth factor-1, insulin and 
prolactin and also has several immunomodulatory effects such as stimulation of T 
cells, natural killer cell and enhances pro-inflammatory cytokine levels [5]. Thus, 
arginine deprived cancer cells can be rescued by activating immunity and increas-
ing the flux of arginine through urea cycle [6]. When a cell is under stress or need 
to proliferate like tumor cell, then the requirement of cellular components such as 
citrulline, nitric oxide and polyamine levels get increase. Therefore arginine synthe-
sis and degradation tremendously increase in cancer cells [7]. Arginine depletion is 
one of the most accepted way to cure tumor cells which are auxotrophic (dependent 
on uptake of extracellular arginine) to arginine. Some tumor cells adapted with 
downregulated arginine metabolizing enzymes for inhibiting the production of 
arginine from the substrates and become arginine auxotrophic [8]. Therefore, dur-
ing cancer some nonessential amino acids turned in to the essential and cancer cell 
becomes auxotrophic for these [9]. As we all know that cancerous cells are associ-
ated with very high survival rates, therefore, some significant improvements are 
required for early detection and treatment of cancer. The idea for cancer treatment 
open the door for some most advanced approaches including; hormone therapy, 
stem cell therapy, immunotherapy and amino acid deprivation therapy [6, 10, 11]. 
One of the most capable amino acid deprivation therapy is arginine deprivation 
where arginine-depleting agents are the main focused and depletion of arginine 
harms the ability of cancer cell metastasize. The mechanisms of arginine impair-
ment are still not clear hence, in this chapter we will try to give a brief discussion 
about the different biosynthesis and catabolic pathways of arginine. How arginine 
deprivation can be focused for cancer therapy for both arginine auxotrophic and 
non-auxotrophic cancerous cells with different mechanism of actions. Moreover, we 
will discuss the impact of arginine deprivation in cell migration through different 
intermediates production such as polyamines and NO.
2. Arginine biosynthesis pathways
Arginine is synthesized from citrulline by the key enzymes ASS1and ASL of the 
urea cycle which also called ornithine cycle and then released into the bloodstream 
(Figure 1a). In large animals, citrulline is produced majorly from NH3, CO2 and 
ornithine by the enzymes OTC and carbamylphosphate synthetase I (CPS1) in the 
small intestine. Citrulline is also recycled to arginine when both argininosuccinate 
ASS1and ASL are present in the same cell and take part in to the citrulline-nitric 
oxide cycle [12]. In contrast arginase and nitric oxide synthetase use arginine as a 
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common substrate and always compete for this substrate [13]. Arginine biosynthe-
sis exhibits diverse pattern of gene organization in bacteria, mammals and plants 
and uses different set of enzymes which catalyze reactions for the formation of a 
key intermediate “ornithine”. Additionally, glutamate is also utilized as the precur-
sor for ornithine synthesis using some intermediates of the urea cycle [13, 14]. 
Extracellular arginine is also a source for ornithine synthesis in cells by enzyme 
arginase 1 [12]. In bacteria and plants, ornithine is synthesized from glutamate in 
five enzymatic steps initiated by the acetylation of glutamate by N-acetylglutamate 
synthase and called N-acetylglutamate synthase pathway (Figure 1b) [15]. Here, 
first ornithine is converted to citrulline by ornithine carbamoyltransferase. 
Figure 1. 
(a) Arginine biosynthesis from glutamine and arginine itself in the urea cycle. (b) Key steps of the arginine 
biosynthesis form glutamine.
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Enzyme ASS1 catalyzes the conversion of citrulline to aspartate and argininosuc-
cinate which is further converted into arginine and fumarate by ASL [16, 17]. 
Ornithine can also be converted back to citrulline by arginine deiminase (ADI) 
pathway in bacteria [18] and by arginase1 pathway in mammals [19]. In both the 
cases citrulline is recycled back to arginine by ASS enzyme [15]. The ability to gen-
erate arginine from citrulline depends on the activity of ASS and ASL [20]. These 
two enzymes are tightly coupled for sensitivity of cells to arginine deprivation and 
their activity depends on their ability to regenerate arginine from the alternative 
sources [21].
3. Arginine catabolic pathways
There are enumerating pathways and enzymes to degrade arginine into other 
biomolecules and intermediates. Five main pathways including; arginine suc-
cinyltransferase (AST) (Figure 2A), arginine decarboxylase (ADC) (Figure 2B), 
Arginase1 (Figure 2C), citrulline- NO ((Figure 2D) and arginine deiminase (ADI) 
(Figure 3) were found to degrade arginine. These pathways are mainly focused by 
the researchers to study arginine degradation and find out its role in different cel-
lular activities and ADI pathway has higher affinity for arginine among all of these 
pathways [22]. The essential site for arginine degradation in ureotelic organisms is 
the liver and second main site is the kidney where arginine is major converted into 
the polyamines, urea, creatine phosphate and NO and transported through blood-
stream into the cells by cationic amino acid transporters (Melis et al, 2008). In bac-
teria arginine is degraded via three key pathways; (i) ADC pathway, here, arginine 
degradation is initiated by decarboxylation of arginine and form agmatine which 
further converted into putrescine by enzyme agmatine ureohydrolase. Putrescine 
is converted into γ- aminobutyric acid by putrescine transaminase and pyrroline 
dehydrogenase and ultimately converted into glutamate and succinate [23].  
Figure 2. 
Arginine biosynthesis by different metabolic pathways such as AST pathway (A), ADC pathway (B), arginase1 
pathway (C) and citrulline-NO pathway (D).
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The enzyme arginine decarboxylase (ADC) is also considered as an important 
enzyme in bacteria [24], plants [25] and in mammalian systems [26]. The infu-
sion of agmatine in the cerebral ventricles increases blood pressure and regulates 
the angiogenic activities [27]. (ii) AST pathway; here, arginine is degraded into 
glutamate, succinate and other intermediates. AST pathway is mainly activated for 
arginine degradation when nitrogen is limited for growth and contributes into the 
production of amino acids [28]. (iii) Arginase1 pathway; this pathway is activated 
when arginine concentration is excess in the media and urea and ornithine are 
produced by enzyme arginase1 during first enzymatic reaction [29]. Here, urea 
does not metabolize further and rapidly excreted into the medium. In arginase1 
pathway, arginine used as the nitrogen and carbon sole sources and less than 3% 
of consumed arginine results in the formation of urea and 36% consumed by the 
route of putrescine and polyamine synthesis [30]. Polyamines produced by this 
pathway are polycations and interact with negatively charged molecules, such as 
DNA, RNA and also with proteins and involved in cellular growth, survival and 
proliferation [31]. Polyamines such as putrescine, spermidine and spermine are very 
tightly regulated by polyamine metabolic pathway [32]. These metabolites used by 
H. pylori to retard the expression of pro-inflammatory cytokines and prevent the 
immune response in stimulated macrophages [33] and also maintain the micro-
environment around their cell in acidic condition for their survival using arginine 
[34]. Cancer and proliferative cells show high levels of polyamines and with this 
feature cancer cells maintain their proliferative properties [32] and high levels of 
polyamines were observed in cancerous cells [35]. It is proposed that both Gram 
negative and positive bacterial cells which contain unusually high AST and ADI 
level grow anaerobically in a complex acidic medium and both the enzymes help to 
raise the pH for the cell survival in the acidic environment [36]. Last but not least, 
arginine deiminase (ADI) pathway degrades arginine to ornithine, ammonia, and 
carbon dioxide and generates one mol of ATP by utilization of per mol of arginine 
[37]. A variety of bacterial cells; both gram positive and gram negative can catabo-
lized arginine through ADI pathway [18]. Enzyme activity of ADI has been detected 
Figure 3. 
degradation of arginine through ADI pathway in the bacterial system.
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in several lactic acid bacteria (LAB), bacilli, clostridia, pseudomonads, aeromonads, 
mycoplasmas, halobacteria, and cyanobacteria [36]. ADI pathway is completed 
by three key enzymes: arginine deiminase (ADI), ornithine transcarbamoylase 
(OTC), and carbamate kinase (CK) as shown in Figure 3. Moreover, in Pseudomonas 
aeruginosa, a fourth gene that encodes a transport protein to exchange arginine and 
ornithine for this pathway has been identified [37]. ADI pathway is most important 
for the bacterial cell survival in the acidic environmental condition because arginine 
degradation by ADI pathway produced ammonia that raises the cytoplasmic and 
extracellular pH and produced ATP use as the energy source for cell survival. In the 
absence of carbohydrate bacteria preferred arginine and utilize it by ADI pathway 
as an alternate energy source to engender energy for cellular growth [20, 38]. 
ADI pathway is regulated at transcriptional level and regulated by transcriptional 
regulator ArgR [3, 37]. Moreover, carbon catabolite repression (CCR) has also been 
confirmed for the expression of ADI pathway in various bacteria. CCR regulates the 
expression of arc operon with glucose and catabolite control protein A (CcpA) [39]. 
CcpA is a transcriptional regulators belonging to the Crp/Fnr family and regulates 
the expression by the binding with regulatory proteins to the cis-acting catabolite 
response elements (cre) located in the promoter regions [20].
4. Impact of arginine degradation in cancer therapy
Cancer cells need excess quantities of specific amino acids for their diverse 
metabolism rate for higher proliferation and become resist for some cell death 
signals. Identification of the metabolic dissimilarly between cancer cells and normal 
cells, cellular metabolism of cancer cells is a therapeutic target and focusing field of 
cancer research [40]. The deprivation of arginine inside cancer cells, which makes 
the cells auxotrophic, has been centered one of the novel approach for cancer treat-
ment [22]. There are several targets have been reported which directly take part in 
cancer mitigation as discussed below;
5. Citrulline-NO cycle
Citrulline is well known as a byproduct of NO synthetase enzyme and can 
be recycled to arginine by the key enzymes ASS1 and ASL. Both these enzymes 
are strongly expressed in liver and kidney then the other cells and tissues. The 
citrulline-nitric oxide cycle stimulates the activation of cytokines such as interferon 
(IFN) [41] and enhances the expression level of ASS1 enzyme as noticed in mouse 
microglial cells [42] and human tumor cell lines [43]. Impaired NO production 
from citrulline has been reported as a vital factor for the abnormal proliferation of 
keratinocytes in psoriasis epidermis. Higher arginase I with induced NO synthetase 
inhibits the keratinocyte proliferation by eliminating the arginine availability [44]. 
Enzymes for arginine metabolism are the potent therapeutic targets to control NO 
and cancerous cell proliferation as shown in Figure 4. In citrulline-NO pathway, 
NO is synthesized from arginine by the three nitric oxide synthase (NOS) isoforms; 
endothelial NOS (eNOS), neuronal NOS (nNOS) and inducible NOS (iNOS) and 
maintain the citrulline -NO cycle in the functional cells [45]. NOS and arginase1 use 
arginine as same substrate but arginase1 down-regulate because NO production by 
competing with NOS for arginine [46]. Remarkably, iNOS and arginase1 activities 
are reciprocally regulated in the cancerous cells by the involvement of cytokines 
and this can be guaranteed for the optimum production of NO but not in immunos-
timulated macrophages [47].
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6. Inhibition of ASS1 activity
The mechanisms which exhibited the loss of ASS1 activity are specifically 
depend on the type of cancerous cell and availability of arginine. ASS1 is a rate-lim-
iting enzyme involved in arginine biosynthesis and has been investigated in numer-
ous cancerous conditions such as melanoma [48], hepatocellular carcinoma [49] 
and pancreatic cancers [50], and the. ASS1-negative cancer cells are auxotrophic 
for arginine and exhibit sensitivity to arginine deprivation [51]. Cancerous cells 
have lack expression of ASS1 enzyme required for arginine biosynthesis which is an 
exogenous source for proteins synthesis and cellular growth [52]. Less ASS1 expres-
sion was recorded as a biomarker in cancer cell and for overall cellular functioning. 
The ASS1-deficient cancers with arginine auxotrophy have been initiated as the 
development of therapeutics by depriving arginine through degradation and trigger 
the apoptosis in arginine auxotrophic cancerous cells [53] as shown in Figure 5. 
The low levels of acetylated polyamine metabolites were found in arginosuccinate 
Figure 4. 
Role of nitric oxide for tumor alimination.
Figure 5. 
Impact of gene ASS1 expression for cancer progression and proliferation and its down-regulation by 
ADI enzyme.
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synthetase-deficient cells, pinpointing the reduction in catabolism and increase 
the expression of polyamine biosynthetic enzymes. This metabolic reprogramming 
elucidates a synthetic lethal interaction between arginosuccinate synthetase loss 
and polyamine metabolism, which could potentially be exploited for the treatment 
of arginosuccinate synthetase-negative cancers [54]. The reason for down-regula-
tion of arginosuccinate synthetase in cancer cells is not cleared properly but always 
remains the center of interest among the cancer researchers [55].
7. ADI obstructed the angiogenetic activity
The enzyme ADI inhibits the tumor growth not only by depletion of arginine 
but also by suppression the angiogenic activity via less NO production [20] as 
shown Figure 6. ADI has an also strong capability to deplete arginine from plasma 
and inhibit NO production which resulting an effective inhibitory role of ADI in 
NO-mediated angiogenesis [56]. During in vitro study, the anti-angiogenic activity 
of ADI to inhibit micro vessel tube formation and migration in endothelial cell cul-
tures was reported by Beloussow et al. [57]. Arginine depletion with the treatment 
of ADI enzyme also alters the level of proline, polyamines, glutamate and succinate. 
Polyamines are essential for tumor proliferation and their less production directly 
affects angiogenesis. Mycoplasma-derived ADI-PEG20 is majorly focused and 
most commonly used as a potential therapeutic agent for clinical investigation with 
different anti-neoplastic activity [58]. Mechanistically, ADI is capable of inhibiting 
the metabolic activity of cancerous cells and take parts in autophagy and apoptosis 
of auxotrophic cells. [59].
Induction of apoptosis
Arginine limitation has also been recorded to induce apoptosis which leads cell 
death in ASS1-negative tumor [60]. Even though, the signaling pathway for apop-
tosis is not clear yet, but it has been reported that apoptosis induced by arginine 
deprivation can be activated via caspase-dependent/independent pathways [1]. The 
limitation of arginine in ASS1-negative mesothelioma cells induced apoptosis via 
Figure 6. 
Role of nitric oxide for angiogenesis and cancer proliferation and migration.
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mitochondrial inner membrane depolarization and Bcl-2-associated X protein (BAX) 
activation which is well known as program type II or caspase-independent cell death 
[55]. It was also reported that ASS1-deficient cancer cells, prolonged autophagy acti-
vated upon ADI treatment and impaired mitochondrial functions by inducing oxida-
tive stress, chromatin autophagy and DNA leakage which finally causes cell death [61] 
as presented in Figure 7. In addition to this arginine limitation by pegylated (PEG) 
arginase causes cell death induced by necrosis as observed in acute myeloid leukemia 
(AML). In contrast, cell cycle arrest in AML cells did not induce cell apoptosis, 
autophagy, and rapid production of reactive oxygen species [62].
8. Role of arginine deprived agents
Deprivations of arginine from cancerous cells not only have a cytotoxic effect on 
cell but also induce specific cell cycle arrest. The cell cycle arrest analysis was done to 
check the surviving population of pancreatic and ovarian cancer cells to examine the 
consequence of arginine deprivation on cell cycle. The first reported arginine depri-
vation agent was ADI enzyme which degraded arginine and prevents cell growth 
s in culture from growing [63]. Human Arginase 1 (HuArgI) is second arginine 
deprivation agent and used to target arginine auxotrophic cancer cell lines and it is 
stable longer in serum, improved catalytic activity and less exposed with immune 
system [64]. Different types of cancerous cell lines undergo different mechanisms 
of cell death when deprived to arginine such as the process of autophagy, when 
cell degrades itself during nutrients limitation leads to starvation and cell death. 
Moreover, autophagy inhibited by HuArgI may indicate no caspase activation, no 
loss in membrane integrity and prevent the cell death caused by apoptosis [65].
9. In inhibition of cell migration
Cell migration is a well accepted attribute of the cancerous cell and arginine 
depletion majorly affect on cell viability and migration [66]. Low level of arginine 
Figure 7. 
Impact of ADI enzyme which leads the apoptosis in cancer cell.
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accompany with the down-regulation of ASS1 expression which may leads the com-
plete auxotrophic and mitigation of cancer cell migration [67]. The migration depen-
dent on arginine requires optimum arginine to be catabolized two specific major 
enzymes nitric oxide synthase and arginase1 and produced citrulline and NO [68]. 
This increased level of promotes the cell viability, proliferation and migration during 
the process of wound healing [69]. Higher level of NO also activates signaling of focal 
adhesion kinase (FAK) cascade, which take parts in integrin assembly and disas-
sembly as shown in Figure 8. Less arginine degradation to NO during wound healing 
showed a decrease in migration of colorectal cancer cells and added citrulline restored 
cell migration [70]. This higher nitric oxide synthase activity was recorded in intes-
tinal epithelial cells in the presence of arginine and citrulline and NO production, 
which directly stimulate the cell migration [71]. The impact of arginine limitation and 
role of FAK was noticed when a study done on human intestinal epithelial cells which 
showed a significant role of NO production and cell migration [72]. Similar to this, 
other enzyme such as ornithine decarboxylase (ODC) used in polyamine biosynthesis 
also play important role in cell migration where polyamines increase the K+ channel 
mediated Ca2+ influx and support to FAK activation [73]. The inhibition of ODC 
enzymes was majorly correlated with abnormal morphology of actin-cytoskeleton of 
metastatic cells migration [74]. Other signals including PI3K, Rho GTPases, microtu-
bules and integrins always found to be interlinked and positive play important role in 
cell polarity by regulating intracellular junctions, cell adhesion, invasion and migra-
tion [75]. Arginine depletion also hamper the RhoA activation in colorectal cancer 
cells and during a report, the increased level of NO was majorly found to be involved 
in the RhoA activation in pancreatic cancer cells [76].
10. Conclusion
Several cancerous cells exhibited a higher metabolic requirement for specific 
amino acids to meet their rapid growth and migration. Therefore, specific amino 
Figure 8. 
Migration and proliferation of cancer.
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acid limitation could be a novel therapy target to cure cancer. Arginine is a well 
known essential amino acid with the ability to regulate cellular activities and 
influence viability, proliferation, motility, migration, adhesion and invasion. There 
are several clinical studies have been reported which clearly explain the impact of 
arginine limitation as a therapy to cure arginine auxotrophic tumors and arginine 
converted in to polyamines and NO, majorly focused for cell proliferation and 
migration. The role of ADI enzyme and less expression of ASS1 gene was found to 
be directly correlated with the production of NO and polyamines and elimination 
of arginine auxotrophic tumors. Some tumors such as hepatocellular carcinoma and 
melanoma are found to be very sensitive for this treatment of arginine limitation 
because here arginine does not take parts in the urea cycle. Thus, the development 
of a new drug and drug resistance due to induction of ASS1 expression leads to 
a potential problem in tumors curing. Overall, the complete mechanism under-
standing of arginine limitation and inhibition of arginine auxotrophic cancer cell 
proliferation and migration is not clear and still further investigation is required to 
understand this cancer therapy.
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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